Skip to content

Thumb ECG IncidenT Atrial fibrillatioN in Diabetes Mellitus

Thumb ECG IncidenT Atrial fibrillatioN in Diabetes Mellitus

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05174390
Acronym
TITAN-DM
Enrollment
600
Registered
2021-12-30
Start date
2021-09-20
Completion date
2022-06-20
Last updated
2021-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Diabetes Mellitus

Keywords

atrial fibrillation, diabetes mellitus, thumb-ECG

Brief summary

Cardiac thromboembolism attributed to atrial fibrillation (AF) constitutes at least one-third of ischemic strokes. Indeed, stroke may be the first manifestation of previously undetected AF. The prevalence is projected to increase 20% the coming decades, especially in age group 65 years and above of age. To add to incidence, the diabetic population have an increased risk yet not properly investigated. In patients with confirmed AF, assessment using the CHA2DS2-VASc score (congestive heart failure, hypertension, age 65 years and above, diabetes mellitus, stroke, vascular disease, age 75 years and above, sexual category), is applied for risk stratification. If the CHA2DS2-VASc score is at least 1, or definitely 2 points typically a non-vitamin K antagonist oral anticoagulant (NOAC) should be prescribed. The chest- and thumb-electrocardiogram (ECG) system Coala Heart Monitor has proven efficacious in detecting AF following recent cryptogenic stroke. This system also showed to be feasible from a patient perspective. Thus, in patients aged 65 years and above with diabetes mellitus at least 2 points are reached. Therefore, patient with these risk factors should be considered for further evaluation for NOAC to prevent stroke, which provides the rational for this study.

Detailed description

Cardiac thromboembolism attributed to atrial fibrillation (AF) constitutes at least one-third of ischemic strokes.The prevalence is projected to increase 20% the coming decades, especially in age group 65 years and above of age. To add to incidence, the diabetic population have an increased risk yet not properly investigated. In patients with confirmed AF, assessment using the CHA2DS2-VASc score (congestive heart failure, hypertension, age 65 years and above, diabetes mellitus, stroke, vascular disease, age 75 years and above, sexual category) , is applied for risk stratification. If the CHA2DS2-VASc score is at least 1, or definitely 2 points typically a Non-vitamin K antagonist Oral AntiCoagulants (NOAC) should be prescribed. The chest- and thumb-electrocardiogram (ECG) system Coala Heart Monitor will be used to detect AF, which showed to be feasible from a patient perspective. Thus, in patients aged 65 years and above with diabetes mellitus at least 2 points are reached. Therefore, patient with these risk factors should be considered for further evaluation for NOAC to prevent stroke, which provides the rational for this study.

Interventions

DIAGNOSTIC_TESTCoala Heart Monitor Pro

thumb- and chest-ECG

Sponsors

Region Gävleborg
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum

Inclusion criteria

* Age 65 years and above * Diabetes mellitus (both type 1 and type 2)

Exclusion criteria

* Treatment with anticoagulation (Eliquis, Lixiana, Pradaxa, Xarelto, Waran) * Pacemaker, implantable cardioverter defibrillator, insertable cardiac monitor * Not able to participate in 90 days follow-up

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with the diagnosis of atrial fibrillation90 daysIncidence of atrial fibrillation during the monitoring period

Secondary

MeasureTime frameDescription
Patient-reported symptoms (descriptive category variables) of atrial fibrillation using a questionnaire in a digital application90 daysSymptoms (questionnaire with the following categories of answers: palpitation, dizziness, dyspnea, chest pain, other) when atrial fibrillation is diagnosed using the patient report (in the digital application with the mentioned categories of symptoms predefined) at the time of ECG transmission.

Countries

Sweden

Contacts

Primary ContactLise-Lotte Sundgren, MSc
lise-lotte.sundgren@regiongavleborg.se+4626154000
Backup ContactPeter Magnusson, MD PhD
peter.magnusson@regiongavleborg.se

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026